![Alan Kozikowski](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alan Kozikowski
Plus aucun poste en cours
Fortune : 484 605 $ au 31/05/2024
Historique de carrière de Alan Kozikowski
Anciens postes connus de Alan Kozikowski
Sociétés | Poste | Début | Fin |
---|---|---|---|
BRIGHT MINDS BIOSCIENCES INC. | Directeur/Membre du Conseil | 31/05/2019 | 07/09/2022 |
Directeur Technique/Scientifique/R&D | 29/10/2020 | 27/06/2022 | |
Fondateur | 31/05/2019 | 07/09/2022 | |
Starwise Therapeutics LLC | Directeur Général | 01/08/2017 | 01/02/2020 |
President | 01/08/2017 | 01/02/2020 | |
University of Illinois | Corporate Officer/Principal | 01/07/2013 | 31/07/2017 |
Actuate Therapeutics, Inc.
![]() Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX. | Fondateur | 01/01/2015 | - |
Georgetown University Medical Center | Corporate Officer/Principal | - | - |
University of Pittsburgh | Corporate Officer/Principal | - | - |
Statistiques
Internationale
Etats-Unis | 7 |
Opérationnelle
Corporate Officer/Principal | 3 |
Founder | 2 |
Director/Board Member | 1 |
Sectorielle
Consumer Services | 4 |
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
BRIGHT MINDS BIOSCIENCES INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Starwise Therapeutics LLC | |
Actuate Therapeutics, Inc.
![]() Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX. | Health Technology |
- Bourse
- Insiders
- Alan Kozikowski
- Expérience